公开(公告)号：AU2017315677B2

公开(公告)日：2021-03-11

申请号：AU2017315677

申请日：2017-08-23

Applicant: ACADEMIA SINICA ,  CHO PHARMA INC

Inventor： LIN NAN-HORNG ,  HUANG LIN-YA ,  SHIVATARE SACHIN S ,  CHEN LI-TZU ,  WONG CHI-HUEY ,  WU CHUNG-YI ,  CHENG TING

IPC: A61K38/47 ,  C12N9/24 ,  C12P21/02

Abstract: A mutant of EndoS2 includes one or more mutations in the sequence of a wild-type EndoS2 (SEQ ID NO: 1), wherein the one or more mutations are in a peptide region located within residues 133-143, residues 177-182, residues 184-189, residues 221-231, and/or residues 227-237, wherein the mutant of EndoS2 has a low hydrolyzing activity and a high tranglycosylation activity, as compared to those of the wild-type EndoS2. A method for preparing an engineered glycoprotein using the mutant of EndoS2 includes coupling an activated oligosaccharide to a glycoprotein acceptor. The activated oligosaccharide is a glycan oxazoline.

公开(公告)号：AU2017231749A1

公开(公告)日：2018-09-20

申请号：AU2017231749

申请日：2017-03-08

Applicant: WONG CHI HUEY ,  ACADEMIA SINICA

Inventor： WONG CHI-HUEY ,  WU CHUNG-YI ,  SHIVATARE SACHIN S

IPC: C08B37/00 ,  C12P19/04 ,  G01N33/50 ,  G01N33/532 ,  G01N33/68

Abstract: The present disclosure relates to novel modular methods for generating a diversity of N-glycans of high mannose, hybrid and complex types. The present disclosure also relates to exemplary arrays of the synthesized N-glycans spotted onto aluminium oxide coated slides. These arrays can be used to detect and analyze binding interactions between the synthesized N-glycansand glycan binding molecules, such as HIV-1 neutralizing antibodies. The present disclosure also relates to methods for identifying agents that bind to various types of molecules on the arrays and to defining the structural elements of the molecules on the arrays that bind to those agents. The arrays and methods provided herein may be used for general epitope identification, drug discovery and as analytical tools. The present disclosure also provides useful glycans and epitope determinants that are useful in detecting, diagnosing, recurrence monitoring and preventing pathological diseases such as HIV.

公开(公告)号：CA3016170A1

公开(公告)日：2017-09-14

申请号：CA3016170

申请日：2017-03-08

Applicant: ACADEMIA SINICA

Inventor： WONG CHI-HUEY ,  WU CHUNG-YI ,  SHIVATARE SACHIN S

IPC: C08B37/00 ,  C12P19/04 ,  G01N33/50 ,  G01N33/532 ,  G01N33/68

Abstract: The present disclosure relates to novel modular methods for generating a diversity of N-glycans of high mannose, hybrid and complex types. The present disclosure also relates to exemplary arrays of the synthesized N-glycans spotted onto aluminium oxide coated slides. These arrays can be used to detect and analyze binding interactions between the synthesized N-glycans and glycan binding molecules, such as HIV-1 neutralizing antibodies. The present disclosure also relates to methods for identifying agents that bind to various types of molecules on the arrays and to defining the structural elements of the molecules on the arrays that bind to those agents. The arrays and methods provided herein may be used for general epitope identification, drug discovery and as analytical tools. The present disclosure also provides useful glycans and epitope determinants that are useful in detecting, diagnosing, recurrence monitoring and preventing pathological diseases such as HIV.

公开(公告)号：CA3034876C

公开(公告)日：2022-10-04

申请号：CA3034876

申请日：2017-08-23

Applicant: CHO PHARMA INC ,  ACADEMIA SINICA ,  LIN NAN HORNG

Inventor： LIN NAN-HORNG ,  HUANG LIN-YA ,  SHIVATARE SACHIN S ,  CHEN LI-TZU ,  WONG CHI-HUEY ,  WU CHUNG-YI ,  CHENG TING

IPC: A61K38/47 ,  C12N9/24 ,  C12P21/02

Abstract: A mutant of EndoS2 includes one or more mutations in the sequence of a wild-type EndoS2 (SEQ ID NO:1), wherein the one or more mutations are in a peptide region located within residues 133-143, residues 177-182, residues 184-189, residues 221-231, and/or residues 227-237, wherein the mutant of EndoS2 has a low hydrolyzing activity and a high transglycosylation activity, as compared to those of the wild-type EndoS2. A method for preparing an engineered glycoprotein using the mutant of EndoS2 includes coupling an activated oligosaccharide to a glycoprotein acceptor. The activated oligosaccharide is a glycan oxazoline.

公开(公告)号：AU2017315677A1

公开(公告)日：2019-04-11

申请号：AU2017315677

申请日：2017-08-23

Applicant: ACADEMIA SINICA ,  CHO PHARMA INC ,  LIN NAN HORNG

Inventor： LIN NAN-HORNG ,  HUANG LIN-YA ,  SHIVATARE SACHIN S ,  CHEN LI-TZU ,  WONG CHI-HUEY ,  WU CHUNG-YI ,  CHENG TING

IPC: A61K38/47 ,  C12N9/24 ,  C12P21/02

Abstract: A mutant of EndoS2 includes one or more mutations in the sequence of a wild-type EndoS2 (SEQ ID NO: 1), wherein the one or more mutations are in a peptide region located within residues 133-143, residues 177-182, residues 184-189, residues 221-231, and/or residues 227-237, wherein the mutant of EndoS2 has a low hydrolyzing activity and a high tranglycosylation activity, as compared to those of the wild-type EndoS2. A method for preparing an engineered glycoprotein using the mutant of EndoS2 includes coupling an activated oligosaccharide to a glycoprotein acceptor. The activated oligosaccharide is a glycan oxazoline.